Johnson & Johnson Q2 2024 Earnings Report
Key Takeaways
Johnson & Johnson reported a 4.3% increase in sales to $22.4 billion and an EPS of $1.93, which decreased by 5.9%. Adjusted EPS increased by 10.2% to $2.82. The company has increased its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical and updated its full-year 2024 adjusted operational EPS guidance to reflect improved performance.
Second-Quarter sales increased by 4.3% to $22.4 Billion.
Second-Quarter Earnings per share (EPS) decreased by 5.9% to $1.93.
Adjusted EPS increased by 10.2% to $2.82.
Full-Year 2024 operational sales guidance increased to reflect the acquisition of Shockwave Medical.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson Revenue by Segment
Forward Guidance
Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact for the recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
Positive Outlook
- Improved performance outlook
- Operational Sales between $89.2B – $89.6B
- Adjusted Operational EPS between $10.00 – $10.10
- Estimated Reported Sales between $88.0B – $88.4B
- Adjusted EPS between $9.97 – $10.07
Challenges Ahead
- Costs associated with recent strategic acquisitions more than offset the improvement
- M&A impact of ($0.68) on Adjusted Operational EPS
- Acquisition of Shockwave Medical
- Acquisition of Proteologix
- Acquisition of NM26 Bispecific Antibody
Revenue & Expenses
Visualization of income flow from segment revenue to net income